SummaryAvalere experts examined evolving stakeholder-specific considerations for reshaping how patients with autoimmune conditions receive care during and after the COVID-19 pandemic.
Treatment for autoimmune conditions continue to see significant Medicare program changes during the COVID-19 pandemic. Current shifts and flexibilities attempt to mitigate the interruptions in care through providing solutions that balance safety and access to necessary treatment. However, these health system disruptions resulting from COVID-19 are significantly reshaping how patients receive care. Unanticipated changes in utilization, such as a large shift from provider-administered to self-administered drugs, will impact coverage, utilization management, and health plan costs. Additionally, there are clinical challenges that must be closely considered by patients and physicians for transition to a new therapy. All healthcare stakeholders will need to understand the immediate and future effects of these changes.
Key topics included:
- Policy shifts during COVID-19
- Current status of Medicare Part B and D
- Provider and patient access and impact
- Future state of the Medicare B and D benefits
- Coverage and cost implications
produces measurable results. Let's work together.